In the evolving landscape of healthcare professional (HCP) engagement, face-to-face interactions remain a cornerstone. They ...

NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...

Collectively, the 100 companies on the list generated revenues of £3.7 billion ($5.06 billion), rising by around £3 billion ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

A new technology elucidated yesterday in the journal Nature has the potential to be a leap forward in DNA synthesis, allowing ...

In this interview conducted during JPM Week in San Francisco, pharmaphorum Editor in Chief Jonah Comstock spoke with Adrian ...

Hopstem has already completed phase 1 testing of hNPC01 in China, with encouraging results, and says it has now reached ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

"The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard ...

The cash injection will also allow Corxel to start phase 2 testing in type 2 diabetes and help to fund a phase 3 programme in ...